We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

6 hedge funds and large institutions have $3.13M invested in CASI Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

48% less capital invested

Capital invested by funds: $6.05M → $3.13M (-$2.92M)

83% less funds holding

Funds holding: 35 → 6 (-29)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 29

Holders
6
Holders Change
-29
Holders Change %
-82.86%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
2
Closed
29
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$49.4K
2
WSCM
Wellington Shields Capital Management
New York
+$5.62K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$1.95M
2
BIT
BlackRock Institutional Trust
California
-$408K
3
WJA
Williams Jones & Associates
New York
-$77K
4
California Public Employees Retirement System
California Public Employees Retirement System
California
-$76K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$70K

CASI Hedge Fund Activity: Q2 2014 in Review

6 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q2 2014, worth a combined $3.13M — down 48% from $6.05M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of CASI and 0 opened new positions — a net loss of 29 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Vanguard Group, adding an estimated $49.4K. The largest seller was Sabby Management, exiting entirely with an estimated $1.95M sold.

  • 6 institutional investors held CASI Pharmaceuticals (CASI) as of Q2 2014, down from 35 in Q1 2014.
  • Funds reported $3.13M of CASI Pharmaceuticals stock for Q2 2014, down 48% quarter-over-quarter.
  • 0 funds opened new CASI Pharmaceuticals positions in Q2 2014 and 29 closed out, a net change of -29 holders.
  • The largest CASI Pharmaceuticals buyer in Q2 2014 was Vanguard Group, an estimated $49.4K added.
  • The largest CASI Pharmaceuticals seller in Q2 2014 was Sabby Management, an estimated $1.95M sold.

Based on aggregated 13F filings for Q2 2014.